Stock listing
Lang & Schwarz:885823 Gilead Sciences, Inc. Aktie
German listing (Lang & Schwarz) of Gilead Sciences, Inc. · home listing NASDAQ:GILD
Follow Gilead Sciences, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GILD
$166.43 USD -2.55 (-1.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GILD
- Day range
- $165.80 – $170.24 USDNov 20, 2026
- Volume
- 7.56M sharesNov 20, 2026
- Market cap
- $206.4B USDAt the close on Nov 20, 2026 · price × 1.24B shares outstanding
- 52-week range
- $116.88 – $176.58 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $929.4M USDMedian day 5.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GILD · Home | $166.43 USD | -2.55 (-1.5%) | 7,555,020 | $168.28 | $170.24 | $165.80 | $168.98 | Close on Nov 20, 2026 |
| TSX:GILD | $33.39 CAD | -0.20 (-0.6%) | 5,300 | $33.59 | $33.87 | $33.39 | $33.59 | Close on Nov 20, 2026 |
| Xetra:GIS | €153.92 EUR | +1.78 (+1.2%) | 534 | €153.12 | €154.96 | €150.92 | €152.14 | Close on Nov 20, 2026 |
| Cboe Canada:GILD | $33.82 CAD | +0.62 (+1.9%) | 1,200 | $33.82 | $33.82 | $33.82 | $33.20 | Close on Nov 20, 2026 |
| BMV:GILD | $3,173.84 MXN | +67.64 (+2.2%) | 221 | $3,173.84 | $3,173.84 | $3,173.84 | $3,106.20 | Close on Nov 19, 2026 |
| Frankfurt:GIS | €153.52 EUR | +3.16 (+2.1%) | 790 | €152.16 | €154.04 | €152.16 | €150.36 | Close on Nov 20, 2026 |
| B3:GILD34 | 82.33 BRL | -0.33 (-0.4%) | 144 | 83.25 | 83.25 | 82.33 | 82.66 | Close on Nov 19, 2026 |
| Dusseldorf:GIS | €153.22 EUR | +0.94 (+0.6%) | — | €151.84 | €153.44 | €151.84 | €152.28 | Close on Nov 20, 2026 |
| Munich:GIS | €154.00 EUR | -0.08 (-0.1%) | — | €154.00 | €154.00 | €154.00 | €154.08 | Close on Nov 20, 2026 |
| Hamburg:GIS | €153.92 EUR | +2.70 (+1.8%) | — | €152.00 | €153.92 | €152.00 | €151.22 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GILD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $166.43 | -2.55 | -1.5% | $168.28 | $170.24 | $165.80 | 7,555,020 | |
| $168.98 | -1.28 | -0.8% | $169.15 | $170.63 | $167.36 | 4,818,627 | |
| $170.26 | +2.68 | +1.6% | $166.12 | $171.36 | $165.72 | 6,220,601 | |
| $167.58 | -0.50 | -0.3% | $171.47 | $171.80 | $166.75 | 4,582,767 | |
| $168.08 | +0.13 | +0.1% | $168.55 | $169.12 | $166.94 | 3,637,151 | |
| $167.95 | -1.78 | -1.0% | $171.18 | $171.70 | $167.93 | 4,228,274 | |
| $169.73 | -1.14 | -0.7% | $169.45 | $170.47 | $168.37 | 4,874,882 | |
| $170.87 | +1.55 | +0.9% | $170.44 | $171.15 | $167.61 | 4,830,415 | |
| $169.32 | +2.43 | +1.5% | $169.00 | $170.11 | $165.99 | 4,289,261 | |
| $166.89 | -0.68 | -0.4% | $164.11 | $169.03 | $164.00 | 5,695,172 | |
| $167.57 | -6.91 | -4.0% | $174.54 | $176.58 | $167.09 | 11,273,348 | |
| $174.48 | +7.01 | +4.2% | $171.89 | $175.41 | $168.88 | 9,555,033 | |
| $167.47 | -2.86 | -1.7% | $170.27 | $172.00 | $167.43 | 6,362,565 | |
| $170.33 | -0.35 | -0.2% | $169.85 | $172.61 | $166.38 | 8,875,746 | |
| $170.68 | +5.07 | +3.1% | $170.00 | $175.65 | $169.00 | 11,363,966 | |
| $165.61 | +6.41 | +4.0% | $162.99 | $165.70 | $160.86 | 8,345,119 | |
| $159.20 | +0.12 | +0.1% | $157.30 | $160.83 | $156.04 | 4,846,215 | |
| $159.08 | +0.39 | +0.2% | $156.42 | $159.28 | $155.76 | 4,931,456 | |
| $158.69 | +2.65 | +1.7% | $157.62 | $159.69 | $157.52 | 6,037,050 | |
| $156.04 | -1.15 | -0.7% | $156.47 | $157.65 | $155.76 | 6,070,932 | |
| $157.19 | +3.62 | +2.4% | $154.24 | $157.42 | $153.00 | 6,210,518 | |
| $153.57 | -2.94 | -1.9% | $154.73 | $155.42 | $151.71 | 6,220,836 | |
| $156.51 | +3.44 | +2.2% | $155.37 | $157.48 | $154.02 | 5,793,495 | |
| $153.07 | -3.12 | -2.0% | $155.39 | $157.24 | $152.92 | 6,835,294 | |
| $156.19 | -1.18 | -0.7% | $157.32 | $157.58 | $155.62 | 7,770,900 | |
| $157.37 | +3.83 | +2.5% | $156.39 | $160.51 | $156.02 | 8,287,500 | |
| $153.54 | +5.62 | +3.8% | $148.19 | $153.76 | $147.48 | 5,756,500 | |
| $147.92 | -2.51 | -1.7% | $151.16 | $151.16 | $147.26 | 5,558,100 | |
| $150.43 | -0.74 | -0.5% | $151.84 | $152.26 | $149.80 | 5,791,400 | |
| $151.17 | +4.07 | +2.8% | $147.23 | $151.44 | $146.10 | 5,802,000 | |
| $147.10 | +0.25 | +0.2% | $146.73 | $147.59 | $144.65 | 4,489,500 | |
| $146.85 | +2.62 | +1.8% | $145.28 | $148.60 | $144.85 | 5,096,700 | |
| $144.23 | -0.40 | -0.3% | $145.11 | $146.14 | $142.60 | 3,723,400 | |
| $144.63 | -0.11 | -0.1% | $143.21 | $145.16 | $142.79 | 6,137,600 | |
| $144.74 | -2.76 | -1.9% | $147.65 | $148.00 | $144.00 | 5,043,900 | |
| $147.50 | -1.55 | -1.0% | $149.44 | $149.44 | $147.19 | 4,438,500 | |
| $149.05 | -2.23 | -1.5% | $150.88 | $151.28 | $148.98 | 5,357,200 | |
| $151.28 | -0.93 | -0.6% | $150.18 | $152.63 | $148.79 | 5,322,400 | |
| $152.21 | +1.28 | +0.8% | $149.80 | $152.74 | $149.41 | 5,076,500 | |
| $150.93 | +1.24 | +0.8% | $150.05 | $151.00 | $148.02 | 5,284,300 | |
| $149.69 | -1.68 | -1.1% | $151.10 | $152.98 | $149.59 | 5,074,700 | |
| $151.37 | -1.30 | -0.9% | $153.60 | $154.20 | $150.06 | 6,191,700 | |
| $152.67 | +2.11 | +1.4% | $150.65 | $153.28 | $148.65 | 5,080,000 | |
| $150.56 | +0.45 | +0.3% | $150.11 | $152.10 | $148.22 | 5,569,200 | |
| $150.11 | -0.78 | -0.5% | $150.56 | $153.23 | $149.57 | 16,412,100 | |
| $150.89 | +3.21 | +2.2% | $148.78 | $151.04 | $146.89 | 7,842,200 | |
| $147.68 | +1.38 | +0.9% | $146.58 | $149.30 | $146.12 | 5,187,900 | |
| $146.30 | -0.11 | -0.1% | $144.00 | $146.35 | $142.94 | 4,532,600 | |
| $146.41 | +2.69 | +1.9% | $144.26 | $146.75 | $143.71 | 4,919,900 | |
| $143.72 | -1.09 | -0.8% | $145.24 | $145.99 | $143.50 | 4,202,400 | |
| $144.81 | -0.84 | -0.6% | $145.07 | $145.91 | $143.67 | 6,019,300 | |
| $145.65 | -0.99 | -0.7% | $145.46 | $147.68 | $145.00 | 4,582,500 | |
| $146.64 | -4.36 | -2.9% | $146.98 | $148.65 | $145.45 | 6,080,100 | |
| $151.00 | -0.22 | -0.1% | $149.23 | $151.19 | $149.23 | 6,181,300 | |
| $151.22 | +1.61 | +1.1% | $150.67 | $151.48 | $148.41 | 4,497,700 | |
| $149.61 | -0.31 | -0.2% | $150.00 | $152.55 | $148.83 | 4,923,200 | |
| $149.92 | +3.58 | +2.4% | $148.52 | $149.96 | $146.92 | 4,868,100 | |
| $146.34 | +0.66 | +0.5% | $144.23 | $147.22 | $143.18 | 6,594,700 | |
| $145.68 | -3.18 | -2.1% | $149.47 | $149.47 | $144.88 | 3,946,900 | |
| $148.86 | +0.77 | +0.5% | $147.30 | $149.11 | $146.01 | 5,014,800 | |
| $148.09 | -0.68 | -0.5% | $148.00 | $149.62 | $147.00 | 5,258,300 | |
| $148.77 | +2.03 | +1.4% | $146.60 | $148.94 | $145.58 | 4,630,300 | |
| $146.74 | +0.62 | +0.4% | $145.93 | $146.84 | $144.59 | 6,182,900 | |
| $146.12 | +2.68 | +1.9% | $144.52 | $147.91 | $143.50 | 5,384,300 | |
| $143.44 | -4.16 | -2.8% | $146.69 | $146.82 | $143.19 | 7,167,600 |
Splits
5 splits since 2001 · NASDAQ:GILD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- Lang & Schwarz:885823
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Latest earnings call · Oct 29, 2026
Gilead Sciences (NASDAQ:GILD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q3 2026 Earnings Presentation
Earnings · 36 slides
Latest news
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Nov 16, 2026
Closed $170.26 (+1.6%) on Nov 17, 2026
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
Nov 12, 2026
Closed $167.95 (-1.0%) on Nov 12, 2026
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Nov 6, 2026
Closed $166.89 (-0.4%) on Nov 6, 2026
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Nov 5, 2026
Closed $167.57 (-4.0%) on Nov 5, 2026
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Nov 4, 2026
Closed $174.48 (+4.2%) on Nov 4, 2026
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Nov 2, 2026
Closed $170.33 (-0.2%) on Nov 2, 2026
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Oct 30, 2026
Closed $170.33 (-0.2%) on Nov 2, 2026
Third Quarter 2026 Summary of Remarks
Oct 29, 2026
Closed $170.68 (+3.1%) on Oct 30, 2026
Gilead Sciences Announces Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $170.68 (+3.1%) on Oct 30, 2026
Gilead Sciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 85 in the last 12 months · 378 in all · newest Nov 16, 2026 · oldest 2020
- Calls
- 31 calls with a replay · 31 with a transcript · latest Oct 29, 2026
- Decks
- 57 decks · latest Oct 29, 2026
Where Gilead Sciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GILD · Home listing | NASDAQ | United States | USD |
| gettex:GIS | gettex | Germany | EUR |
| Tradegate:GIS | Tradegate | Germany | EUR |
| BCBA:GILD | BCBA | Argentina | ARS |
| TSX:GILD | TSX | Canada | CAD |
| Xetra:GIS | Xetra | Germany | EUR |
| Cboe Canada:GILD | Cboe Canada | Canada | CAD |
| Milan:1GILD | Milan | Italy | EUR |
| LS Exchange:885823 | LS Exchange | Germany | EUR |
| BMV:GILD | BMV | Mexico | MXN |
| Lang & Schwarz:885823 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:GIS | Frankfurt | Germany | EUR |
| BCBA:GILDD | BCBA | Argentina | USD |
| Stuttgart:GIS | Stuttgart | Germany | EUR |
| B3:GILD34 | B3 | Brazil | BRL |
| BOATS:GILD | BOATS | United States | USD |
| SIX Swiss:GILD | SIX Swiss | Switzerland | CHF |
| LSIN:0QYQ | LSIN | United Kingdom | USD |
| BIVA:GILD | BIVA | Mexico | MXN |
| EUROTLX:4GILD | EUROTLX | Italy | EUR |
| BCBA:GILDC | BCBA | Argentina | USD |
| VIE:GILD | Vienna | Austria | EUR |
| Dusseldorf:GIS | Dusseldorf | Germany | EUR |
| Munich:GIS | Munich | Germany | EUR |
| Aquis:GISD | Aquis | United Kingdom | EUR |
| BCS:GILD | BCS | Chile | USD |
| Hamburg:GIS | Hamburg | Germany | EUR |
| BCS:GILDCL | BCS | Chile | CLP |
| Aquis:GISD | Aquis | United Kingdom | EUR |
| BVL:GILDUS | BVL | Peru | PEN |
| BX Swiss:GIS | BX Swiss | Switzerland | CHF |
| BCBA:GILDB | BCBA | Argentina | ARS |
| Frankfurt:GIS0 | Frankfurt | Germany | EUR |
| Hanover:GIS | Hanover | Germany | EUR |
| SIX Swiss:GILD.USD | SIX Swiss | Switzerland | USD |
| Turquoise:GILDN | Turquoise | United Kingdom | USD |
| BCBA:GILD.CI | BCBA | Argentina | ARS |
Valuation
EV/sales 7.3× against a median of 7.1×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $226.2B USD
- P/E
- Loss
- EV/sales
- 7.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 15.8×
- Gross margin
- 79.9%
- Operating margin
- −7.6%
- Net margin
- −12.5%
- Debt to equity
- 2.0×
- Beta vs S&P 500
- 0.36
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. · NASDAQ:GILD | US$206.4B | US$226.2B | n/a | 7.3× | n/a | 15.8× | −12.5% | 2.0× | 0.36 |
| Amgen Inc. · NASDAQ:AMGN | US$235.6B | US$276.5B | 25.1× | 7.1× | 15.8× | 16.4× | 24.1% | 3.8× | 0.48 |
| Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN | US$93.57B | US$86.26B | 19.4× | 5.1× | n/a | 2.8× | 28.5% | 0.1× | 0.36 |
| CSL Limited · ASX:CSL | US$62.67B | US$72.05B | n/a | 4.6× | 14.3× | 4.2× | −16.4% | 0.7× | n/a |
| Biogen Inc. · NASDAQ:BIIB | US$36.89B | US$42.88B | 106× | 4.2× | n/a | 1.9× | 3.4% | 0.4× | 0.34 |
| Genmab A/S · OMXCOP:GMAB | US$31.30B | US$34.64B | 42.9× | 8.1× | 24.4× | 4.9× | 17.0% | 0.8× | n/a |
| Insmed Incorporated · NASDAQ:INSM | US$31.01B | US$30.41B | n/a | 20.0× | n/a | 42.7× | −39.9% | 0.8× | 0.01 |
| Roivant Sciences Ltd. · NASDAQ:ROIV | US$27.92B | US$23.82B | n/a | 580× | n/a | 7.0× | −838.2% | 0.0× | 1.00 |
| Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY | US$19.26B | US$15.68B | 7.3× | n/a | n/a | 5.3× | n/a | 0.0× | 0.58 |
| Ascendis Pharma A/S · NASDAQ:ASND | US$16.73B | US$16.15B | 17.1× | 12.2× | 61.1× | 10.0× | 73.5% | 0.3× | 0.49 |
| Exelixis, Inc. · NASDAQ:EXEL | US$15.77B | US$14.88B | 17.8× | 6.0× | n/a | 8.6× | 35.4% | 0.0× | 0.69 |
| Median of the others | US$31.15B | US$32.52B | 19.4× | 7.1× | 20.1× | 6.2× | 17.0% | 0.3× | 0.49 |
Forecasts
15 strong buy · 6 buy · 5 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 175.92 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.99 · 26 analysts
- Revenue, year to Dec 2026
- 31.38B · 25 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Daniel O’Day | Chairman and Chief Executive Officer |
| Andrew Dickinson | Chief Financial Officer |
| Jeffrey A. Bluestone | President |
| Keeley Cain Wettan | Executive Vice President & General Counsel, Legal and Compliance |
| Cindy Perettie | Executive Vice President, Kite |
| Flavius Martin | Executive Vice President, Research |
| Jyoti Mehra | Executive Vice President, Human Resources |
| Dietmar Berger | Chief Medical Officer |
| Johanna Mercier | Chief Commercial & Corporate Affairs Officer |
Board
| Director | Role |
|---|---|
| Daniel O’Day | Chairman and Chief Executive Officer |
| Anthony Welters | Lead Independent Director |
| Harish Manwani | Senior Operating Partner |
| Jacqueline K. Barton | Professor Emerita, California Institute of Technology |
| Sandra J. Horning | Director |
| Ted W. Love | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Gilead Sciences (NASDAQ:GILD) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q4 2025 Earnings Call | Tue, Feb 10, 2026 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q1 2025 Earnings Call | Thu, Apr 24, 2025 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q4 2024 Earnings Call | Tue, Feb 11, 2025 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| Gilead Sciences (NASDAQ:GILD) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
All 31 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | +3.1% |
| Q2 2026 | Aug 4, 2026 · After close | −2.6% |
| Q1 2026 | May 7, 2026 · After close | −2.0% |
| Q4 2025 | Feb 10, 2026 · After close | +5.8% |
| Q3 2025 | Oct 30, 2025 · After close | +1.1% |
| Q2 2025 | Aug 7, 2025 · After close | +8.3% |
| Q1 2025 | Apr 24, 2025 · After close | −2.8% |
| Q4 2024 | Feb 4, 2025 · After close | +1.7% |
| Q3 2024 | Nov 6, 2024 · After close | +6.8% |
| Q2 2024 | Aug 8, 2024 · After close | −2.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · After close | +0.2% |
| Q4 2023 | Feb 6, 2024 · After close | −4.3% |
| Q3 2023 | Nov 7, 2023 · After close | −3.4% |
| Q2 2023 | Aug 3, 2023 · After close | +4.2% |
| Q1 2023 | Apr 27, 2023 · After close | −1.6% |
| Q4 2022 | Feb 2, 2023 · After close | +3.8% |
| Q3 2022 | Oct 27, 2022 · After close | +12.9% |
| Q2 2022 | Aug 2, 2022 · After close | +4.6% |
| Q1 2022 | Apr 28, 2022 · After close | −3.6% |
| Q4 2021 | Feb 1, 2022 · After close | −3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 36 slides | Oct 29, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 36 slides | Aug 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 35 slides | May 7, 2026 |
| Merger or Acquisition (April 2026) | Merger or acquisition | 10 slides | Apr 7, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 40 slides | Feb 10, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 24 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 35 slides | Oct 30, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 35 slides | Aug 7, 2025 |
| fellowship program 2025 guida per la presentazione | 29 slides | Jun 23, 2025 | |
| community award program 2025 guida per la presentazione | 29 slides | Jun 23, 2025 |
Show 50 decks
This page holds 50 of 57 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.4B | 28.8B | 27.1B | 27.3B | 27.3B | 24.7B | 22.4B | 22.1B | 26.1B | 30.4B |
| Cost of revenue | 6.23B | 6.25B | 6.50B | 5.66B | 6.60B | 4.57B | 4.67B | 4.85B | 4.37B | 4.26B |
| Gross profit | 23.2B | 22.5B | 20.6B | 21.6B | 20.7B | 20.1B | 17.8B | 17.3B | 21.7B | 26.1B |
| Research and development | 5.80B | 5.91B | 5.72B | 4.98B | 4.60B | 4.93B | 9.11B | 5.02B | 3.73B | 5.10B |
| Selling, general and administrative | 5.77B | 6.09B | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B |
| Operating income | 10.0B | 1.66B | 7.61B | 7.33B | 9.92B | 4.07B | 4.29B | 8.20B | 14.1B | 17.6B |
| Depreciation and amortization | 370.0M | 381.0M | 354.0M | 323.0M | 329.0M | 288.0M | 255.0M | 226.0M | 233.0M | 177.0M |
| EBITDA | 10.4B | 2.04B | 7.96B | 7.65B | 10.2B | 4.36B | 4.54B | 8.43B | 14.4B | 17.8B |
| Interest expense | 1.02B | 977.0M | 944.0M | 935.0M | 1.00B | 984.0M | 995.0M | 1.08B | 1.12B | 964.0M |
| Income before tax | 9.80B | 690.0M | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.5B | 17.1B |
| Income tax | 1.29B | 211.0M | 1.25B | 1.25B | 2.08B | 1.58B | -204.0M | 2.34B | 8.88B | 3.61B |
| Net income | 8.51B | 480.0M | 5.67B | 4.59B | 6.22B | 123.0M | 5.39B | 5.46B | 4.63B | 13.5B |
| Earnings per share, basic | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 |
| Earnings per share, diluted | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56B | 9.99B | 6.08B | 5.41B | 5.34B | 6.00B | 11.6B | 17.9B | 7.59B | 8.23B |
| Short-term investments | 68.0M | 0 | 1.18B | 973.0M | 1.18B | 1.41B | 12.7B | 12.1B | 17.9B | 3.67B |
| Receivables | 4.91B | 4.42B | 4.66B | 4.78B | 4.49B | 4.89B | 3.58B | 3.33B | 3.85B | 4.51B |
| Inventory | 1.77B | 1.71B | 1.79B | 1.51B | 1.62B | 1.68B | 922.0M | 814.0M | 801.0M | 1.59B |
| Current assets | 18.3B | 19.2B | 16.1B | 14.4B | 14.8B | 16.0B | 30.3B | 35.8B | 31.8B | 19.6B |
| Property, plant and equipment | 5.61B | 5.41B | 5.32B | 5.47B | 5.12B | 4.97B | 4.50B | 4.01B | 3.29B | 2.87B |
| Goodwill | 8.31B | 8.31B | 8.31B | 8.31B | 8.33B | 8.11B | 4.12B | 4.12B | 4.16B | 1.17B |
| Total assets | 59.0B | 59.0B | 62.1B | 63.2B | 68.0B | 68.4B | 61.6B | 63.7B | 70.3B | 57.0B |
| Accounts payable | 715.0M | 833.0M | 550.0M | 905.0M | 705.0M | 844.0M | 713.0M | 790.0M | 814.0M | 1.21B |
| Current liabilities | 11.8B | 12.0B | 11.3B | 11.2B | 11.6B | 11.4B | 9.76B | 10.6B | 11.6B | 9.22B |
| Long-term debt | 22.1B | 24.9B | 23.2B | 23.0B | 25.2B | 28.6B | 22.1B | 24.6B | 30.8B | 26.3B |
| Total debt | 24.9B | 26.7B | 25.0B | 25.2B | 26.7B | 31.4B | 24.6B | 27.3B | 33.5B | 26.3B |
| Shareholders' equity | 22.7B | 19.3B | 22.8B | 21.2B | 21.1B | 18.2B | 22.5B | 21.4B | 20.4B | 18.9B |
| Shares outstanding | 1.24B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.28B | 1.31B | 1.31B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 10.0B | 10.8B | 8.01B | 9.07B | 11.4B | 8.17B | 9.14B | 8.40B | 11.9B | 17.0B |
| Capital spending | -563.0M | -523.0M | -585.0M | -728.0M | -579.0M | -650.0M | -825.0M | -924.0M | -590.0M | -748.0M |
| Free cash flow | 9.46B | 10.3B | 7.42B | 8.34B | 10.8B | 7.52B | 8.32B | 7.48B | 11.3B | 16.3B |
| Cash from investing | -4.79B | -3.45B | -2.27B | -2.47B | -3.13B | -14.6B | -7.82B | 14.4B | -16.1B | -12.0B |
| Cash from financing | -7.75B | -3.43B | -5.13B | -6.47B | -8.88B | 770.0M | -7.63B | -12.3B | 3.39B | -9.72B |
| Dividends paid | -4.00B | -3.92B | -3.81B | -3.71B | -3.60B | -3.45B | -3.22B | -2.97B | -2.73B | -2.46B |
| Share buybacks | -1.92B | -1.15B | -1.00B | -1.40B | -546.0M | -1.58B | -1.75B | -2.90B | -954.0M | -11.0B |
| Change in cash | -2.43B | 3.91B | 673.0M | 74.0M | -659.0M | -5.63B | -6.31B | 10.4B | -641.0M | -4.62B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 13F-HR · Fund holdings report | Nov 5, 2026 | Fund holdings report | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| N-PX | Aug 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 13F-HR · Fund holdings report | Aug 3, 2026 | Fund holdings report | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 20, 2026 | Material contract | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | May 18, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| FWP · Free writing prospectus | May 14, 2026 | Offer document | SEC |
| 424B5 · Prospectus | May 14, 2026 | Offer document | SEC |
| 13F-HR · Fund holdings report | May 8, 2026 | Fund holdings report | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| SC TO-T/A | Apr 28, 2026 | Acquisition or disposal | SEC |
| SC TO-T/A | Apr 17, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| SC TO-T/A | Apr 1, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 20, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| SC TO-T | Mar 6, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| SC TO-C | Feb 23, 2026 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 23, 2026 | Big-stake notice | SEC |
| SC TO-C | Feb 23, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 13F-HR · Fund holdings report | Feb 12, 2026 | Fund holdings report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 19, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 13F-HR · Fund holdings report | Nov 13, 2025 | Fund holdings report | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Gilead Sciences, Inc.’s releases · as of Oct 23, 2026
- Common shares
- 1,240,338,614
- Fully diluted
- 1,240,338,614
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,240,338,614 | Oct 23, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 23, 2026 | 1,240,338,614 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Since at least Feb 1, 2024 |
| Caroline Dorsa Other companies: Duke Energy Corporation (Holding Company) (Director · Since at least May 6, 2021); Illumina, Inc. (Director · Since at least Jan 26, 2017); Biogen Inc. (Director · Since at least Jan 3, 2010); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Avaya Inc (SVP & Chief Financial Officer · Feb 7, 2007 – Oct 25, 2007 · Past); Public Service Enterprise Group Incorporated (Executive VP & CFO · Dec 1, 2006 – Aug 5, 2015 · Past) | SVP, Chief Financial Officer · Nov 5, 2007 – Jan 21, 2008 · Past |
| Sandra J. Horning Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2020); Moderna, Inc. (Director · Since at least Apr 29, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past) | Director · Since at least Jan 28, 2020 |
| Harish Manwani Other companies: QUALCOMM Incorporated (Director · Mar 10, 2020 – Apr 5, 2021 · Past); Nielsen Holdings PLC (Director · May 1, 2019 – Mar 18, 2021 · Past); Whirlpool Corporation (Director · Apr 16, 2019 – Apr 15, 2025 · Past) | Senior Operating Partner · Since at least May 7, 2019 |
| John F. Milligan Other companies: Kailera Therapeutics, Inc. (Board Chair · Since at least Apr 16, 2026); 4D Molecular Therapeutics, Inc. (Executive Chairman · Since at least Dec 10, 2020); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013) | President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past |
| Kelly Kramer Other companies: Figma Inc (Member of our Board of Directors · Since at least Jul 30, 2025); Snowflake Inc. (Director · Since at least Jul 2, 2025); Coinbase Global, Inc. (Director · Since at least Jun 14, 2025) | Director · Since at least May 7, 2025 |
| Paul Carter Other companies: Immatics N.V. (Non-Executive Director · Since at least Mar 18, 2026); Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Alder BioPharmaceuticals Inc (Director · Sep 28, 2015 – Oct 22, 2019 · Past) | EVP Commercial Ops · Jul 1, 2015 – Aug 1, 2016 · Past |
| Anthony Welters Other companies: The Carlyle Group Inc. (Director · Since at least May 1, 2019); Loews Corporation (Director · May 14, 2019 – Mar 3, 2025 · Past) | Director · Since at least Oct 17, 2020 |
| Johanna Mercier Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2021); Arcus Biosciences, Inc. (Director · Jan 29, 2024 – Jan 29, 2024 · Past) | Chief Commercial & Corporate Affairs Officer · Since at least Jul 1, 2019 |
| John McHutchison Other companies: Assembly Biosciences, Inc. (Director · Since at least Aug 6, 2019); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past) | Chief Scientific Off/HeadR&D · Apr 23, 2018 – Feb 6, 2019 · Past |
All 32 people
| Person | Seat |
|---|---|
| Kevin E Lofton Other companies: MiniMed Group, Inc. (Director · Since at least Mar 6, 2026); Medtronic plc. (Director · Since at least Apr 29, 2024) | Director · Dec 28, 2023 – Mar 28, 2024 · Past |
| Olsen Per Wold Other companies: Amarin Corporation plc (Director · Jan 10, 2022 – Jan 10, 2023 · Past); PharmaNet Development Group Inc (Director · Jun 6, 2007 – Mar 20, 2009 · Past) | Director · Jan 28, 2010 – May 6, 2021 · Past |
| Taiyin Yang Other companies: Kronos Bio Inc (Director · Since at least Mar 25, 2021); Kodiak Sciences Inc (Director · Since at least Dec 17, 2019) | SVP, Pharm Dev & Mfg · Jan 25, 2006 – May 8, 2007 · Past |
| Ted W. Love Other companies: Jazz Pharmaceuticals plc (Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025); Royalty Pharma plc (Board Member · Since at least Sep 29, 2025) | Director · Since at least May 4, 2026 |
| Brett A Pletcher Other companies: Cytokinetics, Incorporated (EVP, Chief Legal Officer · Aug 13, 2024 – Aug 30, 2024 · Past) | EVP,Corp Affairs & Gen Counsel · May 9, 2018 – Jun 10, 2022 · Past |
| Dietmar Berger Other companies: Arcus Biosciences, Inc. (Director · Feb 6, 2025 – Feb 6, 2025 · Past) | Chief Medical Officer · Since at least Jan 2, 2025 |
| Javier J. Rodriguez Other companies: DaVita Inc. (Chief Executive Officer, Director · Since at least Apr 11, 2016) | Director · Since at least Jun 15, 2020 |
| John W Madigan Other companies: Boise Cascade, L.L.C. (Director · Feb 5, 2013 – Jun 2, 2014 · Past) | Director · May 6, 2009 – May 9, 2017 · Past |
| Kevin Young Other companies: Quince Therapeutics, Inc. (Director · May 8, 2019 – Jun 8, 2020 · Past) | Chief Operating Officer · May 24, 2016 – Feb 15, 2018 · Past |
| Richard J. Whitley Other companies: Dogwood Therapeutics, Inc. (Director · Since at least Dec 16, 2020) | Director · Mar 28, 2019 – May 6, 2021 · Past |
| Andrew Dickinson | Chief Financial Officer · Since at least Mar 31, 2026 |
| Cindy Perettie | Executive Vice President, Kite · Since at least Apr 28, 2026 |
| Daniel O’Day | Chairman and Chief Executive Officer · Since at least Feb 26, 2019 |
| Erin Burkhart | SVP, Controllership · Since at least Sep 22, 2026 |
| Etienne Davignon | Director · Jan 26, 2006 – May 6, 2016 · Past |
| Flavius Martin | Executive Vice President, Research · Since at least Sep 8, 2026 |
| Gayle E Wilson | Director · May 6, 2009 – May 5, 2020 · Past |
| Jacqueline K. Barton | Director · Since at least May 6, 2021 |
| Jeffrey A. Bluestone | Director · Since at least May 7, 2025 |
| Jyoti Mehra | Executive Vice President, Human Resources · Since at least Nov 5, 2026 |
| Keeley Cain Wettan | Executive Vice President & General Counsel, Legal and Compliance · Since at least Mar 2, 2026 |
| Sandra Patterson | SVP, Controllership · Mar 1, 2023 – Mar 10, 2025 · Past |
Log in to ask 6ix AI your own questions about Gilead Sciences, Inc.